(Circulation. 1997;95:2007-2014.)
© 1997 American Heart Association, Inc.
Articles |
Effect of Single-Drug Therapy on Reduction of Left Ventricular Mass in Mild to Moderate Hypertension
Comparison of Six Antihypertensive Agents
the Cooperative Studies Program of the Medical Research Service of the Department of Veterans Affairs and the Division of Cardiology, Georgetown University Medical Center, Washington, DC.
Correspondence to John S. Gottdiener, MD, Cardiology Division, 5 PHC, Georgetown University Hospital, 3800 Reservoir Rd NW, Washington DC 20007. E-mail gottdien{at}ziplink.net
Background Antihypertensive drugs may differ in their ability to reduce LV mass. Covariates other than drug selection, such as pretreatment LV mass, body weight, the magnitude of blood pressure reduction, race, and age may modify the response of LV mass to therapy.
Methods and Results Patients with mild to moderate hypertension (diastolic blood pressure, 95 to 109 mm Hg) were randomly allocated to treatment with atenolol, captopril, clonidine, diltiazem, hydrochlorothiazide, or prazosin in a double-masked trial. Patients achieving the goal diastolic blood pressure of <90 mm Hg during drug titration entered a 1-year maintenance period. Longitudinal analysis examined changes from baseline echocardiogram in LV mass at 8 weeks and at 1 year, statistically adjusted for pretreatment LV mass, systolic blood pressure, body weight, sodium excretion, physical activity, race, and age. Significant reductions at 1 year in adjusted LV mass were seen for patients in the highest tertile of pretreatment LV mass treated with hydrochlorothiazide (mean, -42.9; 95% confidence limits, -65.5, -20.2 g), captopril (mean, -38.7; 95% confidence limits, -61.0, -16.4 g), and atenolol (mean, -28.1; 95% confidence limits, -50.9, -5.3 g). These treatment effects differed from those of prazosin, diltiazem, or clonidine.
Conclusions Antihypertensive drugs have disparate effects on LV mass independent of the magnitude of blood pressure reduction. Patients with adequate blood pressure control on captopril, hydrochlorothiazide, and atenolol show a reduction of LV mass after 1 year of treatment, whereas patients on diltiazem, clonidine, or prazosin do not.
Key Words: hypertension • hypertrophy • trials • diuretics • drugs • echocardiography
This article has been cited by other articles:
 |
|
 |
|
  E. Gerdts, P. M. Okin, G. de Simone, D. Cramariuc, K. Wachtell, K. Boman, and R. B. Devereux Gender Differences in Left Ventricular Structure and Function During Antihypertensive Treatment: The Losartan Intervention for Endpoint Reduction in Hypertension Study Hypertension, April 1, 2008; 51(4): 1109 - 1114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Heckbert, W. Post, G. D.N. Pearson, D. K. Arnett, A. S. Gomes, M. Jerosch-Herold, W. G. Hundley, J. A. Lima, and D. A. Bluemke Traditional Cardiovascular Risk Factors in Relation to Left Ventricular Mass, Volume, and Systolic Function by Cardiac Magnetic Resonance Imaging: The Multiethnic Study of Atherosclerosis J. Am. Coll. Cardiol., November 8, 2006; (2006) j.jacc.2006.03.072v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. Devereux, B. Dahlof, E. Gerdts, K. Boman, M. S. Nieminen, V. Papademetriou, J. Rokkedal, K. E. Harris, J. M. Edelman, and K. Wachtell Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial Circulation, September 14, 2004; 110(11): 1456 - 1462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. Aurigemma and W. H. Gaasch Diastolic Heart Failure N. Engl. J. Med., September 9, 2004; 351(11): 1097 - 1105. [Full Text] [PDF]
|
|
|
|
|
|
Y. Liao, M. Asakura, S. Takashima, A. Ogai, Y. Asano, Y. Shintani, T. Minamino, H. Asanuma, S. Sanada, J. Kim, et al. Celiprolol, A Vasodilatory {beta}-Blocker, Inhibits Pressure Overload-Induced Cardiac Hypertrophy and Prevents the Transition to Heart Failure via Nitric Oxide-Dependent Mechanisms in Mice Circulation, August 10, 2004; 110(6): 692 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Julius, M. H. Alderman, G. Beevers, B. Dahlof, R. B. Devereux, J. G. Douglas, J. M. Edelman, K. E. Harris, S. E. Kjeldsen, S. Nesbitt, et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: The life study J. Am. Coll. Cardiol., March 17, 2004; 43(6): 1047 - 1055. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Koomans, P. J. Blankestijn, and J. A. Joles Sympathetic Hyperactivity in Chronic Renal Failure: A Wake-up Call J. Am. Soc. Nephrol., March 1, 2004; 15(3): 524 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E Macioch, C D. Katsamakis, J. Robin, P. R Liebson, P. M Meyer, C. Geohas, J. S Raichlen, M. H Davidson, and S. B Feinstein Effect of contrast enhancement on measurement of carotid artery intimal medial thickness Vascular Medicine, February 1, 2004; 9(1): 7 - 12. [Abstract] [PDF]
|
|
|
|
|
|
A. V. Chobanian, G. L. Bakris, H. R. Black, W. C. Cushman, L. A. Green, J. L. Izzo Jr, D. W. Jones, B. J. Materson, S. Oparil, J. T. Wright Jr, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension, December 1, 2003; 42(6): 1206 - 1252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Schlaich, D. M. Kaye, E. Lambert, M. Sommerville, F. Socratous, and M. D. Esler Relation Between Cardiac Sympathetic Activity and Hypertensive Left Ventricular Hypertrophy Circulation, August 5, 2003; 108(5): 560 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hinderliter, A. Sherwood, E. C. D. Gullette, M. Babyak, R. Waugh, A. Georgiades, and J. A. Blumenthal Reduction of Left Ventricular Hypertrophy After Exercise and Weight Loss in Overweight Patients With Mild Hypertension Arch Intern Med, June 24, 2002; 162(12): 1333 - 1339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Verdecchia, G. Carini, A. Circo, E. Dovellini, E. Giovannini, M. Lombardo, P. Solinas, M. Gorini, A. P. Maggioni, and the MAVI Study Group Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study J. Am. Coll. Cardiol., December 1, 2001; 38(7): 1829 - 1835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Devereux, V. Palmieri, N. Sharpe, V. De Quattro, J. N. Bella, G. de Simone, J. F. Walker, R. T. Hahn, and B. Dahlof Effects of Once-Daily Angiotensin-Converting Enzyme Inhibition and Calcium Channel Blockade-Based Antihypertensive Treatment Regimens on Left Ventricular Hypertrophy and Diastolic Filling in Hypertension: The Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) Trial Circulation, September 11, 2001; 104(11): 1248 - 1254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. H. Klungel, S. R. Heckbert, W. T. Longstreth Jr, C. D. Furberg, R. C. Kaplan, N. L. Smith, R. N. Lemaitre, H. G. M. Leufkens, A. de Boer, and B. M. Psaty Antihypertensive Drug Therapies and the Risk of Ischemic Stroke Arch Intern Med, January 8, 2001; 161(1): 37 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Okin, R. B. Devereux, S. Jern, S. E. Kjeldsen, S. Julius, and B. Dahlof Baseline Characteristics in Relation to Electrocardiographic Left Ventricular Hypertrophy in Hypertensive Patients : The Losartan Intervention For Endpoint Reduction (LIFE) in Hypertension Study Hypertension, November 1, 2000; 36(5): 766 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Schwartzkopff, M. Brehm, M. Mundhenke, and B. E. Strauer Repair of Coronary Arterioles After Treatment With Perindopril in Hypertensive Heart Disease Hypertension, August 1, 2000; 36(2): 220 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Gottdiener, A. M. Arnold, G. P. Aurigemma, J. F. Polak, R. P. Tracy, D. W. Kitzman, J. M. Gardin, J. E. Rutledge, and R. C. Boineau Predictors of congestive heart failure in the elderly: the cardiovascular health study J. Am. Coll. Cardiol., May 1, 2000; 35(6): 1628 - 1637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The ALLHAT Officers and Coordinators for the ALLHA Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA, April 19, 2000; 283(15): 1967 - 1975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.A. van Zwieten The influence of antihypertensive drug treatment on the prevention and regression of left ventricular hypertrophy Cardiovasc Res, January 1, 2000; 45(1): 82 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Feldman, N. Campbell, P. Larochelle, P. Bolli, E. D. Burgess, S. G. Carruthers, J. S. Floras, R. B. Haynes, G. Honos, F. H.H. Leenen, et al. 1999 Canadian recommendations for the management of hypertension Can. Med. Assoc. J., December 14, 1999; 161(90120): S1 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Harjai Potential New Cardiovascular Risk Factors: Left Ventricular Hypertrophy, Homocysteine, Lipoprotein(a), Triglycerides, Oxidative Stress, and Fibrinogen Ann Intern Med, September 7, 1999; 131(5): 376 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Gottdiener, P. A. Thurmann, P. Kenedi, A. Schmidt, S. Harder, and N. Rietbrock Influence of the Angiotensin II Antagonist Valsartan on Left Ventricular Hypertrophy in Patients With Essential Hypertension • Response Circulation, August 10, 1999; 100(6): 685 - 688. [Full Text] [PDF]
|
|
|
|
|
|
M. Moser National Recommendations for the Pharmacological Treatment of Hypertension: Should They Be Revised? Arch Intern Med, July 12, 1999; 159(13): 1403 - 1406. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Topouchian, R. Asmar, F. Sayegh, A. Rudnicki, A. Benetos, A. M. Bacri, and M. E. Safar Changes in Arterial Structure and Function Under Trandolapril-Verapamil Combination in Hypertension Stroke, May 1, 1999; 30(5): 1056 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Pitt Regression of Left Ventricular Hypertrophy in Patients With Hypertension : Blockade of the Renin-Angiotensin-Aldosterone System Circulation, November 10, 1998; 98(19): 1987 - 1989. [Full Text] [PDF]
|
|
|
|
|
|
P. A. Thurmann, P. Kenedi, A. Schmidt, S. Harder, and N. Rietbrock Influence of the Angiotensin II Antagonist Valsartan on Left Ventricular Hypertrophy in Patients With Essential Hypertension Circulation, November 10, 1998; 98(19): 2037 - 2042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Gottdiener, D. J. Reda, D. W. Williams, B. J. Materson, W. Cushman, and R. J. Anderson Effect of Single-Drug Therapy on Reduction of Left Atrial Size in Mild to Moderate Hypertension : Comparison of Six Antihypertensive Agents Circulation, July 14, 1998; 98(2): 140 - 148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Chrysant Fixed Low-Dose Drug Combination for the Treatment of Hypertension Arch Fam Med, July 1, 1998; 7(4): 370 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. H. Messerli, E. Grossman, and U. Goldbourt Are {beta}-Blockers Efficacious as First-line Therapy for Hypertension in the Elderly?: A Systematic Review JAMA, June 17, 1998; 279(23): 1903 - 1907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Moser Why Are Physicians Not Prescribing Diuretics More Frequently in the Management of Hypertension? JAMA, June 10, 1998; 279(22): 1813 - 1816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. O. Ofili, J. D. Cohen, J. A. St. Vrain, A. Pearson, T. J. Martin, N. D. Uy, R. Castello, and A. J. Labovitz Effect of Treatment of Isolated Systolic Hypertension on Left Ventricular Mass JAMA, March 11, 1998; 279(10): 778 - 780. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Arch Intern Med, November 24, 1997; 157(21): 2413 - 2446. [Abstract] [PDF]
|
|
|
|
 |
|
 Drug-Specific Regression of LVH Journal Watch Cardiology, May 19, 1997; 1997(519): 2 - 2. [Full Text]
|
|
|
|
 |
|
 ARE ALL ANTIHYPERTENSIVES ALIKE? Journal Watch (General), May 8, 1997; 1997(508): 1 - 1. [Full Text]
|
|
|
|
|
|
R. B. Devereux Do Antihypertensive Drugs Differ in Their Ability to Regress Left Ventricular Hypertrophy? Circulation, April 15, 1997; 95(8): 1983 - 1985. [Full Text]
|
|